Commodore Capital Portfolio
13F Holdings & Position Changes — Last filed Feb 17, 2026
13F Holdings & Position Changes — Last filed Feb 17, 2026
Commodore Capital is a $1.5B biotech-focused hedge fund managed by Egen Atkinson & Michael Kramarz. As of their latest 13F filing (Q4 2025), the fund holds 32 positions worth $1.5B. This quarter they initiated 5 new positions and exited 46. Their largest holding is RLAY ($143.8M).
Commodore initiated 5 new positions and increased 4 this quarter. Portfolio shrank -6.1% to $1.5B. 164 upcoming catalysts across holdings. 2 insider buys detected in portfolio companies.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
No charge for 14 days · Cancel anytime
Commodore Capital held 32 biotech stocks in their 13F portfolio this quarter. Their top positions include RLAY, ALKS, TYRA, XENE, SYRE. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Commodore Capital's tracked biotech portfolio is worth $1.5B across 32 positions, with total assets under management of approximately $1.5B. Portfolio values are based on 13F filings with the SEC.
Commodore Capital initiated 5 new positions this quarter, including ANRO, PALI, REPL, CTNM, LONA. They also increased 4 existing positions.
Commodore Capital fully exited 46 positions this quarter, including AAVXF, ARVN, NKTX, HLXC, RNA and 41 more. They also trimmed 12 existing positions.
Healthcare-focused investment firm co-founded by Egen Atkinson and Michael Kramarz. Takes concentrated positions in biotech and life sciences companies, combining deep scientific analysis with active portfolio management.
| 4 | XENE | Decreased | 1,800,000 | $80.7M |
| 5 | SYRE | Increased | 2,388,245 | $78.2M |
| 6 | COGT | Decreased | 2,196,845 | $78.0M |
| 7 | ELVN | 4,692,809 | $72.3M |
| 8 | CLDX | Decreased | 2,565,000 | $69.7M |
| 9 | AMLX | Increased | 5,650,000 | $68.3M |
| 10 | TERN | Decreased | 1,475,000 | $59.6M |
| 11 | KYMR | 750,000 | $58.4M |
| 12 | SLNO | Decreased | 1,200,000 | $55.6M |
| 13 | NUVL | Decreased | 550,000 | $55.3M |
| 14 | ORKA | 1,753,054 | $53.1M |
| 15 | PHVS | Decreased | 1,889,445 | $52.4M |
| 16 | NRIX | Decreased | 2,275,000 | $43.2M |
| 17 | PTGX | Decreased | 450,000 | $39.3M |
| 18 | ASMB | 1,000,000 | $34.0M |
| 19 | LBRX | 1,500,000 | $33.4M |
| 20 | CTMX | 7,692,300 | $32.8M |
| 21 | ANRO | New | 1,823,196 | $32.5M |
| 22 | PALI | New | 11,445,000 | $26.9M |
| 23 | MNMD | Decreased | 2,000,000 | $26.8M |
| 24 | CNTA | Decreased | 1,000,000 | $25.0M |
| 25 | PEPG | Increased | 3,400,000 | $22.1M |
| 26 | SABSW | 4,401,500 | $16.5M |
| 27 | REPL | New | 1,425,000 | $13.9M |
| 28 | IKT | 5,397,488 | $11.1M |
| 29 | CTNM | New | 816,326 | $9.3M |
| 30 | AVTX | 483,000 | $8.8M |
| 31 | LONA | New | 464,398 | $3.5M |
| 32 | DRUG | Decreased | 18,851 | $1.5M |
| Q2 2025 |
| $1.1B |
| -0.9% |
| Q1 2025 | $1.1B | -4.3% |
| Q4 2024 | $1.1B | -15.2% |
| Q3 2024 | $1.3B | +11.7% |
| Q2 2024 | $1.2B | +0.9% |
| Q1 2024 | $1.2B | +31.6% |
| Q4 2023 | $885.1M | +40.6% |
| Q3 2023 | $629.4M | -2.5% |
| Q2 2023 | $645.6M | +47.2% |
| Q1 2023 | $438.7M | — |